Bevacizumab News and Research

RSS
Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.
Chromosomal instability may predict which patients will respond better to colorectal cancer drug

Chromosomal instability may predict which patients will respond better to colorectal cancer drug

New clinical trial initiated on experimental vaccine to stop the spread of glioblastoma

New clinical trial initiated on experimental vaccine to stop the spread of glioblastoma

Additional inhibitor could be key to helping anti-VEGF therapies overcome resistance in glioblastoma

Additional inhibitor could be key to helping anti-VEGF therapies overcome resistance in glioblastoma

Saving sight of millions by making eye injections safe and comfortable

Saving sight of millions by making eye injections safe and comfortable

Scientists move one step further in developing eye drops to treat age-related macular degeneration

Scientists move one step further in developing eye drops to treat age-related macular degeneration

Phase 1 clinical trial of poliovirus therapy shows long-term survival benefit for recurrent glioblastoma

Phase 1 clinical trial of poliovirus therapy shows long-term survival benefit for recurrent glioblastoma

Researchers explore targeted second-line treatment for colorectal cancer

Researchers explore targeted second-line treatment for colorectal cancer

Adding chemotherapy to treatment regimen can give children with PVS a chance to grow up

Adding chemotherapy to treatment regimen can give children with PVS a chance to grow up

Ludwig scientists develop and test individualized ovarian cancer vaccine

Ludwig scientists develop and test individualized ovarian cancer vaccine

Vascular stabilization biomarker helps optimize timing of anticancer therapies

Vascular stabilization biomarker helps optimize timing of anticancer therapies

Treating metastatic breast cancer with immunotherapy

Treating metastatic breast cancer with immunotherapy

Study shows safety, efficacy of intravenous bevacizumab treatment for HHT related bleeding

Study shows safety, efficacy of intravenous bevacizumab treatment for HHT related bleeding

Scientists discover new target for anti-angiogenic tumor therapy

Scientists discover new target for anti-angiogenic tumor therapy

New first line combination therapy shows promising results in patients with advanced NSCLC

New first line combination therapy shows promising results in patients with advanced NSCLC

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Risk factors, symptoms, diagnosis and treatment of ovarian cancer

Risk factors, symptoms, diagnosis and treatment of ovarian cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Combination immunotherapy as second or third line treatment of mesothelioma shows promising results

Tumor irradiation may prolong survival of NSCLC patients undergoing novel chemotherapy formulation

Tumor irradiation may prolong survival of NSCLC patients undergoing novel chemotherapy formulation